Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avanir Pharmaceuticals has announced that the European Patent Office has granted the company a new patent, extending the period of commercial exclusivity for its lead drug candidate Zenvia into 2023.
Subscribe to our email newsletter
The new European patent expands the available Zenvia dose ranges under prior patent protection and encompasses the company’s current clinical development programs in pseudobulbar affect and diabetic peripheral neuropathic pain, as well as other neurologic conditions.
Keith Katkin, president and CEO of Avanir, said: “This new patent significantly extends the period of Zenvia commercial exclusivity throughout Europe and enhances the global potential of our primary asset.”